Value proposition

CorWave develops and manufactures innovative implantable blood pumps based on a breakthrough membrane technology.

CorWave is a French company developing innovative cardiac assist
devices.

CorWave’s wave membrane pump is a breakthrough technology that
differs from today’s commercially available left ventricular assist devices
(LVADs) by its physiological operation, designed to mimic a pulse and
blood flow rates similar to those of a healthy heart. Ultimately,
CorWave’s membrane pump technology is expected to reduce the
complications associated with current devices and improve the
management of heart failure patients.

A member of the French Tech 120, CorWave was founded in 2012 by start-up studio MD Start and is funded by renowned investors including Bpifrance, Exor Ventures, EIC Fund, Financière Arbevel, M&L Healthcare, Novo Holdings, Seventure Partners, Sofinnova Partners, Ysios Capital and Vlerick Group. The company has secured over €80 million in equity and employs over seventy people.